spinal cord injury
NurExone Targets H1 2027 IND Filing for ExoPTEN
NurExone Biologic Inc. (TSXV: NRX; OTCQB: NRXBF; FSE: J90) is targeting a potential investigational new drug submission for ExoPTEN during the first half of 2027 as it advances preclinical and manufacturing activities for the experimental therapy. The timeline was included in NurExone’s second-quarter update, released August 31. ExoPTEN is an exosome-based candidate being developed for…
